Dr. Shore discusses effects of darolutamide on urinary and bowel symptoms

“We [found] that patients' overall [total] bowel symptoms scores were improved for those of the patients who received the active therapeutic treatment of [darolutamide] versus placebo,” says Neal D. Shore, MD, FACS.

In this video, Neal D. Shore, MD, FACS, discusses the background and findings of the study, “Impact of darolutamide on local symptoms in patients with nonmetastatic castration-resistant prostate cancer,” presented recently at the 2021 American Urological Association annual meeting. Shore is the director of the Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, South Carolina.